NASDAQ: LUCDLucid Diagnostics Inc Stock
$1.75+0.03 (+1.74%)
Updated Jun 8, 2023
LUCD Price
$1.75
Fair Value Price
N/A
Market Cap
$76.52M
52 Week Low
$1.11
52 Week High
$3.64
P/E
-1.09x
P/B
3.07x
P/S
90.47x
PEG
N/A
Dividend Yield
N/A
Revenue
$634.00k
Earnings
-$60.15M
Gross Margin
-622.7%
Operating Margin
-9,481.86%
Profit Margin
-9,487.1%
Debt to Equity
0.97
Operating Cash Flow
-$31M
Beta
0.97
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
LUCD Overview
Lucid Diagnostics Incorporated is developing products to diagnose and treat conditions of the esophagus, including conditions arising from chronic heartburn which may lead to esophageal cancer. The company's lead products include EsoGuard, a laboratory developed esophageal DNA test, and EsoCheck, an esophageal cell collection device. Lucid Diagnostics was incorporated in 2018 and is headquartered in New York, NY.
Zen Score
–
Industry Average (29)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how LUCD scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
LUCD is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
LUCD is good value based on its book value relative to its share price (3.07x), compared to the US Medical Devices industry average (3.92x)
P/B vs Industry Valuation
LUCD is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more LUCD due diligence checks available for Premium users.
Be the first to know about important LUCD news, forecast changes, insider trades & much more!
LUCD News
Valuation
LUCD price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.09x
Industry
788.88x
Market
52.58x
LUCD price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
3.07x
Industry
3.92x
LUCD is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
LUCD's financial health
Profit margin
Revenue
$446.0k
Net Income
-$16.2M
Profit Margin
-3,642.8%
LUCD's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
LUCD's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$49.1M
Liabilities
$24.2M
Debt to equity
0.97
LUCD's short-term assets ($41.72M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
LUCD's short-term assets ($41.72M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
LUCD's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$7.0M
Investing
-$17.0k
Financing
$24.1M
LUCD's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
LUCD vs Medical Device Stocks
Lucid Diagnostics Stock FAQ
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.